Top News

PharmEasy-owned diagnostics major Thyrocare Technologies reported a sharp rise in its bottom line in Q4 FY26, with consolidated net profit surging 128% to ₹48.7 Cr from ₹21.3 Cr in the corresponding quarter last year.

On a sequential basis, profit rose 22% from ₹39.9 Cr, driven by strong operating leverage and volume growth.

Revenue from operations grew 20% to ₹224 Cr during the quarter under review from ₹187.2 Cr in Q4 FY25. Sequentially, revenue rose about 5% from ₹213.3 Cr.

Growth was led by continued momentum in its core pathology segment, which expanded 21% YoY, with franchise revenue up 21% and partnership revenue rising 23%.

Total expenses increased in line with business expansion, growing 13.9% YoY to ₹164.4 Cr. Employee benefit expenses rose 26% YoY to ₹32.6 Cr, while other expenses climbed 21% YoY to ₹55.8 Cr. Cost of materials consumed increased 15% YoY to ₹56.7 Cr.

Thyrocare’s EBITDA grew 31% YoY and 8% QoQ to ₹75.1 Cr. EBITDA margin improved to 34% from 31% in Q4 FY25 and about 33% in Q3 FY26.

Operationally, the company processed 5.9 Cr tests in Q4 FY26, marking a strong 29% YoY growth, reinforcing its leadership in diagnostic test volumes in India.

During the quarter, Thyrocare expanded its specialty diagnostics portfolio by launching advanced allergy testing (250+ SKUs) and entering the genomics segment with non-invasive prenatal testing (NIPT) as part of its push into precision diagnostics.

For the full financial year FY26, the company reported a 21% YoY rise in revenue to ₹829 Cr, while net profit increased 81% YoY to ₹162.9 Cr. EBITDA grew 38% YoY to ₹262 Cr, highlighting sustained operating leverage and scale benefits.

(The story will be updated soon)

The post PharmEasy-Owned Thyrocare’s Q4 Profit Jumps 128% YoY To ₹48.7 Cr appeared first on Inc42 Media.